Bioloom has successfully completed preclinical studies and is preparing for Phase 1 clinical trials. The company has garnered significant interest from key opinion leaders in the autoimmune disease space and has established collaborations with leading academic institutions.
Organizations Involved
SOSV, Y Combinator, Stanford University
Founders
Alice Chen, David Lee
Company Description
Bioloom is a biotech company specializing in developing novel therapeutics for autoimmune diseases by leveraging its proprietary platform that combines machine learning algorithms with high-throughput screening technologies. The company's approach enables the rapid identification of potential drug candidates with high efficacy and low toxicity, offering a promising solution for patients suffering from autoimmune disorders.